Breast Cancer Version 5.2024
Central Nervous System Cancers Version 3.2024
Cervical Cancer Version 4.2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025
Dermatofibrosarcoma Protuberans Version 1.2025
Hairy Cell Leukemia Version 1.2025
Hepatocellular Carcinoma Version 3.2024
Hodgkin Lymphoma Version 4.2024
Kaposi Sarcoma Version 2.2024
Melanoma: Cutaneous Version 3.2024
Mesothelioma: Peritoneal Version 3.2024
Mesothelioma: Pleural Version 2.2024
Non-Small Cell Lung Cancer Version 11.2024
Soft Tissue Sarcoma Version 3.2024
NCCN Guidelines with Evidence Blocks - Central Nervous System Cancers Version 3.2024
NCCN Guidelines with Evidence Blocks - Cervical Cancer Version 4.2024
NCCN Guidelines with Evidence Blocks - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025
NCCN Guidelines with Evidence Blocks - Dermatofibrosarcoma Protuberans Version 1.2025
NCCN Guidelines with Evidence Blocks - Hairy Cell Leukemia Version 1.2025
NCCN Guidelines with Evidence Blocks - Hepatocellular Carcinoma Version 3.2024
NCCN Guidelines with Evidence Blocks - Melanoma: Cutaneous Version 3.2024
NCCN Guidelines with Evidence Blocks - Non-Small Cell Lung Cancer Version 11.2024
NCCN Guidelines with Evidence Blocks - Soft Tissue Sarcoma Version 3.2024
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Version 2.2024
Lung Cancer Screening Version 1.2025
Antiemesis Version 2.2024
Hematopoietic Growth Factors Version 1.2025
Prevention and Treatment of Cancer-Related Infections Version 3.2024
Adolescent and Young Adult (AYA) Oncology Version 2.2025
Cancer in People with HIV Version 3.2024